



UK National  
Screening Committee

UK National Screening Committee  
Modification to the Bowel Cancer Screening Programme- an evidence review

Consultation comments pro-forma

<b>Name:</b>	Sarah May	<b>Email address:</b>	sarahmay@ibms.org
<b>Organisation (if appropriate):</b>	Institute of Biomedical Science		
<b>Role:</b>	Deputy Chief Executive		
<b>Do you consent to your name being published on the UK NSC website alongside your response?</b>			
Yes <input checked="" type="checkbox"/> No <input type="checkbox"/>			
<b>Section and / or page number</b>	<b>Text or issue to which comments relate</b>	<b>Comment</b>	
		<i>Please use a new row for each comment and add extra rows as required.</i>	
3	Comparisons with gFOBT	The new test is clearly better than the current FOB test for both specificity and sensitivity and also ease of use for both patients and laboratory staff.	
		The evidence for use of FIT is strong, and there is also evidence that	

		faecal haemoglobin concentrations are age and sex dependent (McDonald et al, Clin Chem Lab Med. 2011) which makes the use of a quantitative method important
4	Costs	The economic modelling looks sound and clearly supports the new test 3.
5		More detailed information is needed on the costings and timelines for IT system development and technological solutions for automating the pre-analytics in the laboratory. At present they are somewhat generalised statements of intent rather than having any real substance to them

Please return to Adrian Byrtus (Evidence Review & Policy Development Manager) [adrian.byrtus@nhs.net](mailto:adrian.byrtus@nhs.net) by **30<sup>th</sup> October**